Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents

Nuclear Medicine and Biology

Volumn 29, Issue 7, 2002, Pages 761-770

  Zheng, Qi Huang ^a   Fei, Xiangshu ^a   Liu, Xuan ^a   Wang, Ji Quan ^a   Bin Sun, Hui ^a   Mock, Bruce H ^a   Lee Stone, K ^a   Martinez, Tanya D ^a   Miller, Kathy D ^a   Sledge, George W ^a   Hutchins, Gary D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

11C Methyl halo CGS 27023A analogs; Breast cancer; Carbon 11; Matrix metalloproteinase inhibitor; Positron emission tomography; Radiotracer

Indexed keywords

AMINO ACID; CARBON 11; CGS 27023A; DRUG DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR; METHYLTRIFLATE; N (METHOXY) 2 [[(2 BROMOPHENYL)SULFONYL] (3 PICOLYL)AMINO] 3 METHYLBUTANAMIDE; N (METHOXY) 2 [[(2 CHLOROPHENYL)SULFONYL] (3 PICOLYL)AMINO] 3 METHYLBUTANAMIDE; N (METHOXY) 2 [[(2 FLUOROPHENYL)SULFONYL] (3 PICOLYL)AMINO] 3 METHYLBUTANAMIDE; N (METHOXY) 2 [[(3 BROMOPHENYL)SULFONYL] (3 PICOLYL)AMINO] 3 METHYLBUTANAMIDE; N (METHOXY) 2 [[(3 CHLOROPHENYL)SULFONYL] (3 PICOLYL)AMINO] 3 METHYLBUTANAMIDE; N (METHOXY) 2 [[(4 BROMOPHENYL)SULFONYL] (3 PICOLYL)AMINO] 3 METHYLBUTANAMIDE; N (METHOXY) 2 [[(4 CHLOROPHENYL)SULFONYL] (3 PICOLYL)AMINO] 3 METHYLBUTANAMIDE; N (METHOXY) 2 [[(4 FLUOROPHENYL)SULFONYL] (3 PICOLYL)AMINO] 3 METHYLBUTANAMIDE; N (METHOXY) 2 [[(4 IODOPHENYL)SULFONYL] (3 PICOLYL)AMINO] 3 METHYLBUTANAMIDE; OXYGEN; TRACER; TRIFLUOROMETHANESULFONIC ACID; UNCLASSIFIED DRUG; VALINE; CARBON; DIAGNOSTIC AGENT; HYDROXAMIC ACID; METALLOPROTEINASE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SULFONAMIDE; TUMOR MARKER;

ARTICLE; BREAST CARCINOMA; DRUG SYNTHESIS; IMAGING; ISOLATION PROCEDURE; ISOTOPE LABELING; METHYLATION; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; SOLID PHASE EXTRACTION; TIME; ANIMAL; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ANTAGONISM; EVALUATION; HUMAN; METABOLISM; METHODOLOGY; SCINTISCANNING; SYNTHESIS;

ANIMALS; BREAST NEOPLASMS; CARBON RADIOISOTOPES; HUMANS; HYDROXAMIC ACIDS; METALLOENDOPEPTIDASES; PROTEASE INHIBITORS; PYRAZINES; RADIOPHARMACEUTICALS; SULFONAMIDES; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0036792110     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(02)00338-4     Document Type: Article

References (38)

1. Afzal S., Lalani el.-N., Foulkes W.D., Boyce B., Tickle S., Cardillo M.R., Baker T., Pignatelli M., Stamp G.W. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab. Invest. 74:1996;406-421.
2. Almstead N.G., Bradley R.S., Pikul S., De B., Natchus M.G., Taiwo Y.O., Gu F., Williams L.E., Hynd B.A., Janusz M.J., Dunaway C.M., Mieling G.E. Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors. J. Med. Chem. 42:1999;4547-4562.
3. Babine R.E., Bender S.L. Molecular recognition of protein-ligand complexes Applications to drug design . Chem. Rev. 97:1997;1359-1472.
4. Brown P.D. Matrix metalloproteinase inhibitors. Breast Cancer Res. Treat. 52:1998;125-136.
5. Brown S., Bernardo M.M., Li Z.H., Kotra L.P., Tanaka Y., Fridman R., Mobashery S. Potent and selective mechanism-based inhibition of gelatinases. J. Am. Chem. Soc. 122:2000;6799-6800.
6. Cheng M., De B., Almstead N.G., Pikul S., Dowty M.E., Dietsch C.R., Dunaway C.M., Gu F., Hsieh L.C., Janusz M.J., Taiwo Y.O., Natchus M.G., Hudlicky T., Mandel M. Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold. J. Med. Chem. 42:1999;5426-5436.
7. Cheng M., De B., Pikul S., Almstead N.G., Natchus M.G., Anastasio M.V., McPhail S.J., Snider C.E., Taiwo Y.O., Chen L.Y., Dunaway C.M., Gu F., Dowty M.E., Mieling G.E., Janusz M.J., Wang-Weigand S. Design and synthesis of piperazine-based matrix metalloproteinase inhibitors. J. Med. Chem. 43:2000;369-380.
8. 11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents. J. Labelled Cpd. Radiopharm. 45:2002;449-470.
9. Greenwald R.A., Zucker S., Golub L.M., Inhibition of matrix metalloproteinases, therapeutic applications, Ann. N.Y. Acad. Sci. 878:1999;1-761.
10. Hagmann W.K., Lark M.W., Becker J.W. Inhibition of matrix metalloproteinases. Bristol J.A., Ann. Rep. in Med. Chem. Vol. 31:1996;231-240 Academic Press, New York.
11. Hahnel E., Harvey J.M., Joyce R., Robbins P.D., Sterrett G.F., Hahnel R. Stromelysin-3 expression in breast cancer biopsies clinico-pathological correlations . Int. J. Cancer. 55:1993;771-774.
12. Hanessian S., MacKay D.B., Moitessier N. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors. J. Med. Chem. 44:2001;3074-3082.
13. Jeng A.Y., Chou M., Parker D.T. Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase. Bioorg. Med. Chem. Lett. 8:1998;897-902.
14. 11C]methyl triflate. Appl. Radiat. Isot. 43:1992;1383-1385.
15. Kiyama R., Tamura Y., Watanabe F., Tsuzuki H., Ohtani M., Yodo M. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors. J. Med. Chem. 42:1999;1273-1278.
16. MacPherson L.J., Bayburt E.K., Capparelli M.P., Carroll B.J., Goldstein R., Justice M.R., Zhu L., Hu S., Melton R.A., Fryer L., Goldberg R.L., Doughty J.R., Spirito S., Blancuzzi V., Wilson D., O'Byrne E.M., Ganu V., Parker D.T. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 40:1997;2525-2532.
17. 11C]methyl triflate. Nucl. Med. Biol. 26:1999;467-471.
18. Nagase H., Fields C.G., Fields G.B. Design and characterization of a fluorogenic substrate selectively hydrolyzed by stromelysin 1 (matrix metalloproteinase-3). J. Biol. Chem. 269:1994;20952-20957.
19. Natchus M.G., Bookland R.G., De B., Almstead N.G., Pikul S., Janusz M.J., Heitmeyer S.A., Hookfin E.B., Hsieh L.C., Dowty M.E., Dietsch C.R., Patel V.S., Garver S.M., Gu F., Pokross M.E., Mieling G.E., Baker T.R., Foltz D.J., Peng S.X., Bornes D.M., Strojnowski M.J., Taiwo Y.O. Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. J. Med. Chem. 43:2000;4948-4963.
20. Natchus M.G., Bookland R.G., Laufersweiler M.J., Pikul S., Almstead N.G., De B., Janusz M.J., Hsieh L.C., Gu F., Pokross M.E., Patel V.S., Garver S.M., Peng S.X., Branch T.M., King S.L., Baker T.R., Foltz D.J., Mieling G.E. Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines. J. Med. Chem. 44:2001;1060-1071.
21. Pikul S., McDow Dunham K.L., Almstead N.G., De B., Natchus M.G., Anastasio M.V., McPhail S.J., Snider C.E., Taiwo Y.O., Chen L., Dunaway C.M., Gu F., Mieling G.E. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases. J. Med. Chem. 42:1999;87-94.
22. Pikul S., McDow K.L., Almstead Dunham, N.G., De B., Natchus M.G., Anastasio M.V., McPhail S.J., Snider C.E., Rydel Y.O Taiwo, T., Dunaway C.M., Gu F., Mieling G.E. Discovery of potent, achiral matrix metalloproteinase inhibitors. J. Med. Chem. 41:1998;3568-3571.
23. Pikul S., Ohler N.E., Ciszewski G., Laufersweiler M.C., Almstead N.G., De B., Natchus M.G., Hsieh L.C., Janusz M.J., Peng S.X., Branch T.M., King S.L., Taiwo Y.O., Mieling G.E. Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. J Med. Chem. 44:2001;2499-2502.
24. Price A., Shi Q., Morris D., Wilcox M.E., Brasher P.M., Rewcastle N.B., Shalinsky D., Zou H., Appelt K., Johnston R.N., Yong V.W., Edwards D., Forsyth P. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin. Cancer Res. 5:1999;845-854.
25. Rasmussen H.S., McCann P.P. Matrix metalloproteinase inhibition as a novel anticancer strategy a review with special focus on batimastat and marimastat . Pharmacol. Ther. 75:1997;69-75.
26. Robinson R.P., Laird E.R., Blake J.F., Bordner J., Donahue K.M., Lopresti-Morrow L.L., Mitchell P.G., Reese M.R., Reeves L.M., Stam E.J., Yocum S.A. Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold. J. Med. Chem. 43:2000;2293-2296.
27. Schroder J., Henke A., Wenzel H., Brandstetter H., Stammler H.G., Stammler A., Pfeiffer W.D., Tschesche H. Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. J. Med. Chem. 44:2001;3231-3243.
28. Scozzafava A., Supuran C.T. Carbonic anhydrase and matrix metalloproteinase inhibitors sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes . J. Med. Chem. 43:2000;3677-3687.
29. Shuttleworth S. Harvey A.L., Advances in drug discovery techniques. 1998;115 John Wiley & Sons Ltd, New York.
30. Steward W.P. Marimastat (BB2516) current status of development . Cancer Chemother. Pharmacol. 43:(Suppl):1999;S56-S60.
31. Summers J.B., Davidsen S.K. Matrix metalloproteinase inhibitors and cancer. Bristol J.A., Ann. Rep. in Med. Chem. Vol. 33:1998;131-140 Academic Press, New York.
32. Tamura Y., Watanabe F., Nakatani T., Yasui K., Fuji M., Komurasaki T., Tsuzuki H., Maekawa R., Yoshioka T., Kawada K., Sugita K., Ohtani M. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2) N-sulfonylamino acid derivatives . J. Med. Chem. 41:1998;640-649.
33. Whittaker M. Discovery of protease inhibitors using targeted libraries. Curr. Opin. Chem. Biol. 2:1998;386-396.
34. Whittaker M., Flooyd C.D., Brown P., Gearing A.J.H. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem. Rev. 99:1999;2735-2776.
35. 11C]beta-CIT labeled at nitrogen or oxygen positions. Nucl. Med. Biol. 23:1996;981-986.
36. 11C]Nor-β-CIPPT . J. Labelled Cpd. Radiopharm. 40:(Suppl.1):1997;551-553.
37. Zheng Q.-H., Mulholland G.K. Isomerization study of aryltropane analogs of cocaine. Syn. Commun. 30:2000;333-340.
38. 11C]HE-β-CNT new PET monoamine transporter radiotracers containing polar hydroxyethyl groups, accessible from the corresponding fluoroethyl derivatives . J. Labelled Cpd Radiopharm. 40:(Suppl.1):1997;548-550.